On August 14, 2026, an update was recorded for a clinical trial involving gonadorelin, registered as NCT04812366. The study is titled "Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer." According to the listing, the trial is in Phase 2 and its current status is recruiting.
The trial is described as an umbrella study, meaning it evaluates multiple treatment approaches selected based on genomic biomarkers, in patients with high risk localized prostate cancer. Gonadorelin is included among the compounds relevant to this study as reflected in the trial record.
No results have been posted for this trial as of the date of this update. The status reflects that recruitment is ongoing rather than any findings, safety data, or efficacy conclusions. No outcomes, endpoints, or comparative data are provided in the available event information beyond the phase and recruitment status.
Readers should note this update reflects only administrative trial status information as registered publicly. It does not represent a claim about the therapeutic effect of gonadorelin in this setting. For more background on this compound, see the linked compound overview.